A Phase I Trial To Evaluate Zidovudine (ZDV) in HIV-1 Infected Pregnant Women and Their Offspring

Inclusion Criteria Concurrent Medication: Allowed: * In one group of four or more patients, methadone maintenance treatment. * Acetaminophen for periods less than 72 hours. * Supportive therapy including blood and blood products, vaginal creams, antiemetics, antidiarrheals, and cough medicines as deemed necessary by the responsible investigator. * Iron, multivitamins, and short course of treatment for correctable medical problems, such as urinary tract infection. Concurrent Treatment: Allowed: * Blood and blood products as supportive therapy. Patients must have HIV-1 infection and be in the third trimester of pregnancy. Additional patients will also be receiving methadone maintenance therapy for intravenous drug use. Exclusion Criteria Concurrent Medication: Excluded: * Systemic medications during this pregnancy. * Acetaminophen for periods more than 72 hours. Patients will be excluded from the study for the following reasons: * Complications of pregnancy. * History of poor medical compliance related to factors other than accessibility of care. * Insistence on breast-feeding during the first 24 hours of the birth of the child. * Evidence of preexisting fetal anomalies at = or \> 20 weeks gestation as noted by an abnormal level 2 sonogram prior to study entry. * Evidence of fetal intolerance of the intrauterine environment including intrauterine growth retardation, oligohydramnios, polyhydramnios, biophysical profile equal to or less than 6 for fetus with a gestational age \> 32 weeks, congenital malformation, fetal hydrous or ascites. * Previous systemic infection including influenza during this pregnancy. * Malabsorption syndrome and/or history of frequent diarrhea that might interfere with absorption of oral zidovudine (AZT). Prior Medication: Excluded: * Antivirals and other systemic medications during this pregnancy. Patients may not have any of the following diseases or symptoms: * Obstetrical complications: * Poor obstetrical history including but not limited to recurrent spontaneous abortions, previous preterm or low-birth-weight infant, congenital anomalies (past or present pregnancy), premature rupture of membranes, multiple gestation, intrauterine fetal death (this pregnancy), and placenta previa or abruptio (this pregnancy). * Medical complications: * Conditions including but not limited to insulin-dependent diabetes mellitus (IDDM), hypertensive disorders which include preeclampsia, eclampsia, chronic hypertension, cardiovascular disease including rheumatic or congenital heart disease, collagen vascular disease, endocarditis, and renal disease. * Hematologic complications. * Neurologic complications. * Pulmonary complications. History of illicit drug use during this pregnancy. * Note: This exclusion applies only to the first six or more women to enter this study who do not have a history of intravenous drug use. Four or more patients: * Intravenous drug use, if enrolled in a methadone maintenance program.